SCHEMBL200546

SCHEMBL200546

Cc1c(C(=O)O)c(=O)n(-c2ccccc2)n1CC(C)(C)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 14/20 0.49
IGF1R P08069 2/20 0.45
MET P08581 2/20 0.45
KDR P35968 2/20 0.45
MST1R Q04912 2/20 0.45
AURKA O14965 1/20 0.45
JAK2 O60674 1/20 0.45
RPS6KA5 O75582 1/20 0.45
ABL1 P00519 1/20 0.45
INSR P06213 1/20 0.45
LCK P06239 1/20 0.45
FES P07332 1/20 0.45
CSF1R P07333 1/20 0.45
LYN P07948 1/20 0.45
RET P07949 1/20 0.45
FGR P09769 1/20 0.45
KIT P10721 1/20 0.45
PIM1 P11309 1/20 0.45
FGFR1 P11362 1/20 0.45
SRC P12931 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2353865 0.89 ABCB1 (0.47) ABCB1IGF1RMETKDRMST1R
SCHEMBL198287 0.83 ABCB1 (0.44) ABCB1IGF1RMETKDRMST1R
SCHEMBL15550275 0.82 ABCB1 (0.52) ABCB1DPP4MAOAMAOBTSHR
SCHEMBL198057 0.80 ABCB1 (0.50) ABCB1DPP4MAOAMAOBTSHR
SCHEMBL13467426 0.80 ALDH1A1 (0.60) ABCB1IGF1RMETKDRMST1R
SCHEMBL12181067 0.78 MET (0.62) ABCB1IGF1RMETKDRMST1R
SCHEMBL2949349 0.78 ABCB1 (0.59) ABCB1
SCHEMBL377244 0.78 ABCB1 (0.59) ABCB1
SCHEMBL377122 0.78 ABCB1 (0.59) ABCB1
SCHEMBL2950401 0.77 MET (0.53) ABCB1IGF1RMETKDRMST1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP claimed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US claimed
US-20130225569-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US claimed
EP-2609100-A2 FUROPYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2013-07-03 EP claimed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO claimed
US-20240293386-A1 NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR LG CHEM, LTD. (KR) 2024-09-05 US disclosed
WO-2024134514-A1 NOVEL COMPOUND AS RON INHIBITOR 주식회사 엘지화학 2024-06-27 WO disclosed
US-20240150325-A1 NOVEL COMPOUND AS PROTEIN KINASE INHIBITORS LG CHEM, LTD. (KR) 2024-05-09 US disclosed
EP-4332106-A1 NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR LG Chem, Ltd. (KR) 2024-03-06 EP disclosed
CN-117355533-A Novel compounds as protein kinase inhibitors 株式会社LG化学 2024-01-05 CN disclosed
EP-4273140-A1 NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR Lg Chem, Ltd. (KR) 2023-11-08 EP disclosed
CN-116745279-A Novel compounds as protein kinase inhibitors 株式会社LG化学 2023-09-12 CN disclosed
US-20080312232-A1 Substituted amide derivatives and methods of use AMGEN INC. (US) 2008-12-18 US disclosed
US-20080234268-A1 Bis-aryl amide derivatives and methods of use AMGEN INC. (US) 2008-09-25 US disclosed
US-20080234268-A1 Bis-aryl amide derivatives and methods of use AMGEN INC. (US) 2008-09-25 US disclosed
US-20080234268-A1 Bis-aryl amide derivatives and methods of use AMGEN INC. (US) 2008-09-25 US disclosed
WO-2008086014-A2 BIS-ARYL AMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER AMGEN INC. (US) 2008-07-17 WO disclosed
WO-2008086014-A2 BIS-ARYL AMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER AMGEN INC. (US) 2008-07-17 WO disclosed
EP-1881976-A1 SUBSTITUTED AMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS Amgen Inc., (US) 2008-01-30 EP disclosed
WO-2006116713-A1 SUBSTITUTED AMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS AMGEN INC. (US) 2006-11-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240150325-A1 NOVEL COMPOUND AS PROTEIN KINASE INHIBITORS MAP3K20, SBK3, MAPKAPK2 ABCB1 3308/4885IGF1R 1036/4885MET 686/4885
US-20080312232-A1 Substituted amide derivatives and methods of use HGF, HGFAC, MET ABCB1 455/4885IGF1R 57/4885MET 3/4885
US-20130225569-A1 FUROPYRIDINE DERIVATIVES SYK, FCGRT, SSB ABCB1 700/4885IGF1R 204/4885MET 1482/4885
US-20240293386-A1 NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR MAP3K20, SBK3, MAPKAPK2 ABCB1 3631/4885IGF1R 1075/4885MET 657/4885
US-20080234268-A1 Bis-aryl amide derivatives and methods of use MET, REL, NAT1 ABCB1 104/4885IGF1R 216/4885MET 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.